Back to News
Market Impact: 0.12
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationCompany Fundamentals
Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR) alleging violations of §§10(b) and 20(a). The news is a legal/regulatory update without disclosed financial impact in the excerpt, but it adds overhang risk for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
CAPR-0.75
More News
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- Last-Minute Lawsuit Upends Cable One’s $480 Million Mega Broadband Deal
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.